{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:16:22Z","timestamp":1788992182681,"version":"build-2803163510"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Multidrug-resistant\n                      <jats:italic toggle=\"yes\">Stenotrophomonas maltophilia<\/jats:italic>\n                      (MDR Sm) is an emerging neonatal pathogen with limited therapeutic options. Cefiderocol shows potent in vitro activity, but neonatal clinical data are scarce.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation:<\/jats:title>\n                    <jats:p>We report an extremely preterm male infant (27\u2009+\u20092 weeks, 800\u2009g) who developed ventilator-associated pneumonia due to a metallo-\u03b2-lactamase-producing MDR Sm on day 50 of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and Outcomes:<\/jats:title>\n                    <jats:p>Targeted therapy with cefiderocol (100\u2009mg\/kg q8h) plus trimethoprim-sulfamethoxazole (7\u2009mg\/kg q8h) led to extubation within 24 hours, C-reactive protein normalization within 72 hours, and radiographic clearance by day 14. No adverse events occurred. The infant was discharged on room air and remained well at 6-month follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Cefiderocol may represent a safe and effective salvage option for MDR Sm ventilator-associated pneumonia in extremely preterm neonates, but further pharmacokinetic, pharmacodynamic and stewardship studies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005108","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T05:00:42Z","timestamp":1765861242000},"page":"489-491","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Cefiderocol in Combination With Trimethoprim-sulfamethoxazole for Multidrug-resistant Stenotrophomonas maltophilia Ventilator-associated Pneumonia in an Extremely Preterm Infant: A Case Report"],"prefix":"10.1097","volume":"45","author":[{"given":"Simona","family":"Pesce","sequence":"first","affiliation":[{"name":"Neonatology and Neonatal Intensive Care Unit, \u201cSan Carlo\u201d Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Scavone","sequence":"additional","affiliation":[{"name":"Neonatology and Neonatal Intensive Care Unit, \u201cSan Carlo\u201d Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Guarini","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, \u201cSan Giovanni\u201d Hospital, Lagonegro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Gilio","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, \u201cSan Carlo\u201d Hospital, Potenza, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1445-6979","authenticated-orcid":false,"given":"Luisiana","family":"Stolfi","sequence":"additional","affiliation":[{"name":"Neonatology and Neonatal Intensive Care Unit, \u201cSan Carlo\u201d Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"R1-20260508","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.mib.2017.10.028","article-title":"Global antimicrobial resistance in Gram-negative pathogens and clinical need.","volume":"39","author":"Theuretzbacher","year":"2017","journal-title":"Curr Opin Microbiol"},{"key":"R2-20260508","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3390\/antibiotics12121747","article-title":"Pharmacokinetic and pharmacodynamic considerations of antibiotic use in neonates.","volume":"12","author":"Regazzi","year":"2023","journal-title":"Antibiotics"},{"key":"R3-20260508","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R4-20260508","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R5-20260508","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R6-20260508","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s15010-024-02404-9","article-title":"Successful therapy of a newborn with Stenotrophomonas maltophilia nosocomial pneumonia with cefiderocol.","volume":"53","author":"Trauth","year":"2025","journal-title":"Infection"},{"key":"R7-20260508","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/INF.0000000000004051","article-title":"Successful use of cefiderocol to treat a multidrug-resistant Stenotrophomonas maltophilia ventilator-associated pneumonia in an extremely preterm neonate.","volume":"42","author":"Koirala","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20260508","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/CMR.00019-11","article-title":"Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.","volume":"25","author":"Brooke","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"R9-20260508","first-page":"5","article-title":"Cefiderocol as a treatment option for Stenotrophomonas maltophilia causing hospital-acquired\/ventilator-associated pneumonia.","volume":"15","author":"Rashid","year":"2023","journal-title":"Cureus"},{"key":"R10-20260508","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13613-023-01146-5","article-title":"Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.","volume":"13","author":"Viale","year":"2023","journal-title":"Ann Intensive Care"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:00:30Z","timestamp":1778212830000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005108","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}